TY - JOUR T1 - Cutaneous Lymphomas — Part II: Other Cutaneous Lymphomas JO - Actas Dermo-Sifiliográficas T2 - AU - Pujol,R.M. AU - Gallardo,F. SN - 15782190 M3 - 10.1016/j.adengl.2020.12.008 DO - 10.1016/j.adengl.2020.12.008 UR - https://www.actasdermo.org/es-cutaneous-lymphomas-part-ii-articulo-S1578219020303759 AB - Primary cutaneous T-cell lymphomas other than mycosis fungoides, Sézary syndrome, and lymphoproliferative CD30+ disorders are few, accounting for less than 5% of all cutaneous lymphomas. A cytotoxic phenotype is characteristic of these tumors, and their clinical behavior is usually aggressive. Patients often present with extracutaneous symptoms or develop them shortly after diagnosis. Management is usually multidisciplinary, and intensive systemic therapy and bone marrow transplantation should be considered. Cutaneous B-cell lymphomas account for approximately 30% of primary cutaneous lymphomas. They make up a heterogeneous group of tumors that have different clinical and pathological features. Clinical course also varies. Presenting as papules, nodules, or tumors of variable reddish–violaceous coloring, the lesions may be solitary or multiple and occasionally form clusters. There may also be generalized lesions, present at multiple sites on the trunk, head, or extremities. Three well-defined groups of primary cutaneous lymphoma have been reported: follicle center lymphoma; marginal zone lymphoma, which follows an indolent course; and a diffuse large B-cell lymphoma, leg type, which follows an aggressive course. ER -